Profile

New User

New to Graphy Publications? Create an account to get started today.

Registered Users

Have an account? Sign in now.

How to Cite | Author Information | Publication History
International Journal of Clinical Research & Trials Volume 5 (2020), Article ID 5:IJCRT-154, 7 pages
https://doi.org/10.15344/2456-8007/2020/154
Research Article
Incidence and Associated Risk Factors of Chemotherapy-Induced Cardiomyopathy in the African American and Afro-Caribbean Populations

Mohammed Al-Sadawi1, Kurnvir Singh1, Violeta Capric1, Amena Mohiuddin1, Michael Haddadin1, Arismendy Nunez2, Shakil Shaikh2, Inna Bukharovich3 and Samy I. McFarlane1,*

1Department of Internal Medicine, State University of New York: Downstate Medical Center, Brooklyn, NY 11203, United States
2Department of Cardiovascular Medicine, State University of New York: Downstate Medical Center, Brooklyn, NY 11203, United States
3Department of Cardiovascular Medicine, Kings County Hospital Center, Brooklyn, NY 11203, United States
Prof. Samy I. McFarlane, College of Medicine, Department of Medicine, Division of Endocrinology, Internal Medicine Residency Program Director, State University of New York, Downstate Medical Center, 450 Clarkson Ave, Box 50, Brooklyn, New York, 11203-2098, USA. Tel: 718-270- 6707, Fax 718-270-4488; E-mail: smcfarlane@downstate.edu
19 November 2020; 07 December 2020; 09 December 2020
Al-Sadawi M, Singh K, Capric V, Mohiuddin A, Haddadin M, et al. (2020) Incidence and Associated Risk Factors of Chemotherapy-Induced Cardiomyopathy in the African American and Afro-Caribbean Populations. Int J Clin Res Trials 5: 154. doi: https://doi.org/10.15344/2456-8007/2020/154
© 2020 Al-Sadawi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

References

  1. Shakir DK, Rasul KI (2009) Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management. J Clin Med Res 1: 8-12. [CrossRef] [Google Scholar] [PubMed]
  2. Eschenhagen T, Force T, Ewer MS, de Keulenaer GW, Suter TM, et al. (2011) Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 13: 1-10. [CrossRef] [Google Scholar] [PubMed]
  3. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, et al. (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37: 2129-2200. [CrossRef] [PubMed]
  4. Piper SE, McDonagh TA (2015) Chemotherapy-related Cardiomyopathy. Eur Cardiol 10: 19-24. [CrossRef] [PubMed]
  5. Sawyer DB (2013) Anthracyclines and heart failure. N Engl J Med 368: 1154-1156. [CrossRef] [Google Scholar] [PubMed]
  6. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, et al. (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91: 710-717. [CrossRef] [Google Scholar] [PubMed]
  7. Chen MH, Kerkela R, Force T (2008) Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 118: 84-95. [CrossRef] [Google Scholar] [PubMed]
  8. Onitilo AA, Engel JM, Stankowski RV (2014) Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors. Ther Adv Drug Saf 5: 154-166. [CrossRef] [Google Scholar] [PubMed]
  9. Baron KB, Brown JR, Heiss BL, Marshall J, Tait N, et al. (2014) Trastuzumab-induced cardiomyopathy: incidence and associated risk factors in an inner-city population. J Card Fail 20: 555-559. [CrossRef] [Google Scholar] [PubMed]
  10. Hasan S, Dinh K, Lombardo F, Kark J (2004) Doxorubicin cardiotoxicity in African Americans. J Natl Med Assoc 96: 196-199. [Google Scholar] [PubMed]
  11. Litvak A, Batukbhai B, Russell SD, Tsai HL, Rosner GL, et al. (2018) Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer. Cancer 124: 1904-1911. [CrossRef] [Google Scholar] [PubMed]
  12. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684. [CrossRef] [Google Scholar] [PubMed]
  13. Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, et al. (2012) Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 104: 1293-1305. [CrossRef] [Google Scholar] [PubMed]
  14. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, et al. (2014) Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 27: 911-939. [CrossRef] [Google Scholar] [PubMed]
  15. Stevens PL, Lenihan DJ (2015) Cardiotoxicity due to Chemotherapy: the Role of Biomarkers. Curr Cardiol Rep 17: 603. [CrossRef] [Google Scholar] [PubMed]
  16. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, et al. (2010) Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 55: 213-220. [CrossRef] [Google Scholar] [PubMed]
  17. Early Breast Cancer Trialists' Collaborative Group (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379: 432-444. [CrossRef] [Google Scholar] [PubMed]
  18. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, et al. (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375: 377-84. [CrossRef] [Google Scholar] [PubMed]
  19. Litvak A, Batukbhai B, Russell SD, Tsai HL, Rosner GL, et al. (2018) Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer. Cancer 124: 1904-1911. [CrossRef] [Google Scholar] [PubMed]
  20. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, et al. (2002) ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8: 459-465. [CrossRef] [Google Scholar] [PubMed]
  21. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, et al. (2017) 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 389: 1195-1205. [CrossRef] [Google Scholar] [PubMed]
  22. Swain SM, Whaley FS, Ewer MS (2008) Congestive heart failure in patients treated with doxorubicin. Cancer 97: 2869-2879. [CrossRef] [Google Scholar] [PubMed]
  23. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, et al. (2005) Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. N Engl J Med 353: 1659-72. [CrossRef] [Google Scholar] [PubMed]
  24. Rugo HS, Brufsky AM, Ulcickas Yood M, Tripathy D, Kaufman PA, et al. (2013) Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat 141: 461-470. [CrossRef] [Google Scholar] [PubMed]
  25. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, et al. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726. [CrossRef] [Google Scholar] [PubMed]
  26. Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, et al. (2006) Long-Term Cardiac Tolerability of Trastuzumab in Metastatic Breast Cancer: The M.D. Anderson Cancer Center Experience. J Clin Oncol 24: 4107-4115. [CrossRef] [Google Scholar] [PubMed]
  27. Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, et al. (2007) Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 25: 3859-3865. [CrossRef] [Google Scholar] [PubMed]
  28. Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, et al. (2008) Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26: 1231-1238. [CrossRef] [Google Scholar] [PubMed]
  29. Untch M, Muscholl M, Tjulandin S, Jonat W, Meerpohl HG, et al. (2010) First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. J Clin Oncol 28: 1473-1480. [CrossRef] [Google Scholar] [PubMed]
  30. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, et al. (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365: 1273-1283. [CrossRef] [Google Scholar] [PubMed]
  31. Romond EH, Jeong JH, Rastogi P, Swain SM, Geyer CE Jr, et al. (2012) Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30: 3792-3799. [CrossRef] [Google Scholar] [PubMed]
  32. Azambuja E, Procter MJ, Veldhuisen DJv, Agbor-Tarh D, Metzger-Filho O, et al. (2014) Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01). J Clin Oncol 32: 2159-2165. [CrossRef] [Google Scholar] [PubMed]
  33. Advani PP, Ballman KV, Dockter TJ, Colon-Otero G, Perez EA, et al. (2016) Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial. J Clin Oncol 34: 581-587. [CrossRef] [Google Scholar] [PubMed]
  34. Yoon HJ, Kim KH, Kim JY, Park HJ, Cho JY, et al. (2016) Chemotherapy-Induced Left Ventricular Dysfunction in Patients with Breast Cancer. J Breast Cancer 19: 402-409. [CrossRef] [PubMed]
  35. Dang C, Guo H, Najita J, Yardley D, Marcom K, et al. (2016) Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. JAMA Oncol 2: 29-36. [CrossRef] [Google Scholar] [PubMed]
  36. Horenstein MS, Vander Heide RS, L'Ecuyer TJ (2000) Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol Genet Metab 71: 436-444. [CrossRef] [Google Scholar] [PubMed]
  37. Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE, et al. (2005) Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 131: 561-578. [CrossRef] [Google Scholar] [PubMed]
  38. Hasan S, Dinh K, Lombardo F, Kark J (2004) Doxorubicin cardiotoxicity in African Americans. J Natl Med Assoc 96: 196-199. [Google Scholar] [PubMed]
  39. Jensen BV, Skovsgaard T, Nielsen SL (2002) Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 13: 699-709. [CrossRef] [PubMed]
  40. Azambuja E, Paesmans M, Beauduin M, Vindevoghel A, Cornez N, et al. (2009) Long-Term Benefit of High-Dose Epirubicin in Adjuvant Chemotherapy for Node-Positive Breast Cancer: 15-Year Efficacy Results of the Belgian Multicentre Study. J Clin Oncol 27: 720-725. [CrossRef] [Google Scholar] [PubMed]
  41. Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, et al. (2008) New Insight Into Epirubicin Cardiac Toxicity: Competing Risks Analysis of 1097 Breast Cancer Patients. J Natl Cancer Inst 100: 1058-1067. [CrossRef] [Google Scholar] [PubMed]
  42. Hufnagle JJ, Goyal A (2020) Radiation Therapy Induced Cardiac Toxicity. Stat Pearls. Treasure Island (FL): StatPearls Publishing. [Google Scholar]
  43. Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, et al. (2016) Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 37: 1671-1680. [CrossRef] [Google Scholar] [PubMed]
  44. Wheeler SB, Reeder-Hayes KE, Carey LA (2013) Disparities in breast cancer treatment and outcomes: biological, social, and health system determinants and opportunities for research. Oncologist 18: 986-993. [CrossRef] [Google Scholar] [PubMed]
  45. Finkelman BS, Putt M, Wang T, Wang L, Narayan H, et al. (2017) Arginine-Nitric Oxide Metabolites and Cardiac Dysfunction in Patients With Breast Cancer. J Am Coll Cardiol 70: 152-162. [CrossRef] [Google Scholar] [PubMed]
Best viewed in Mozilla Firefox, Google Chrome, Safari, Above IE 9.0 version
Privacy Policy | Copyright & Permissions
Copyright © 2013-2024 Graphy Publications, All Rights Reserved.